

# Yukihisa Fujinaga

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8331207/publications.pdf>

Version: 2024-02-01

39  
papers

355  
citations

932766

10  
h-index

996533

15  
g-index

41  
all docs

41  
docs citations

41  
times ranked

380  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients. <i>Antibiotics</i> , 2020, 9, 145.  | 1.5 | 33        |
| 2  | Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis. <i>Hepatology Research</i> , 2019, 49, 284-295.   | 1.8 | 25        |
| 3  | Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5589.   | 1.8 | 21        |
| 4  | Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis. <i>Microorganisms</i> , 2020, 8, 925.   | 1.6 | 18        |
| 5  | TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. <i>Cells</i> , 2019, 8, 1153.  | 1.8 | 16        |
| 6  | Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor. <i>Clinical Endoscopy</i> , 2021, 54, 371-378.  | 0.6 | 16        |
| 7  | Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6921.  | 1.8 | 16        |
| 8  | Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2164. | 1.8 | 12        |
| 9  | Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. <i>Hepatology Communications</i> , 2017, 1, 928-945.   | 2.0 | 11        |
| 10 | Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1635.  | 1.0 | 11        |
| 11 | Association between ADAMTS13 activity and VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 7232-7241.  | 1.4 | 11        |
| 12 | Glycogenic Hepatopathy in Type 1 Diabetes Mellitus. <i>Internal Medicine</i> , 2018, 57, 1087-1092.  | 0.3 | 10        |
| 13 | The association between sarcopenia and endotoxin in patients with alcoholic cirrhosis. <i>Medicine (United States)</i> , 2021, 100, e27212.  | 0.4 | 10        |
| 14 | Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis. <i>Medicine (United States)</i> , 2021, 100, e27403.   | 0.4 | 10        |
| 15 | Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. <i>Hepatology Research</i> , 2019, 49, 1147-1161.  | 1.8 | 9         |
| 16 | Identification of clinical risk factors for histological progression of primary biliary cholangitis. <i>Hepatology Research</i> , 2019, 49, 1015-1025.   | 1.8 | 9         |
| 17 | Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis. <i>Hepatology Research</i> , 2019, 49, 232-238.   | 1.8 | 9         |
| 18 | Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males. <i>Nutrients</i> , 2020, 12, 1036.  | 1.7 | 9         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure. <i>Journal of Clinical Medicine</i> , 2020, 9, 1467.  | 1.0 | 8         |
| 20 | ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability. <i>Journal of Clinical Medicine</i> , 2022, 11, 1835.  | 1.0 | 8         |
| 21 | Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3510.   | 1.0 | 7         |
| 22 | Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute-on-chronic liver failure development and prognosis in patients with liver cirrhosis. <i>Hepatology Research</i> , 2022, 52, 390-400.   | 1.8 | 7         |
| 23 | Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis. <i>Digestive and Liver Disease</i> , 2022, 54, 1392-1402.  | 0.4 | 7         |
| 24 | Effect of furosemide on muscle cramps in patients with liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 76-81.   | 1.4 | 6         |
| 25 | Association between Equol Production Status and Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11904.  | 1.8 | 6         |
| 26 | Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia. <i>Digestive Diseases</i> , 2020, 38, 329-334.  | 0.8 | 5         |
| 27 | Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center study. <i>Hepatology Research</i> , 2020, 50, 1101-1105.  | 1.8 | 5         |
| 28 | The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis. <i>Hepatology Research</i> , 2021, 51, 31-38.  | 1.8 | 5         |
| 29 | Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 887-897.  | 0.8 | 5         |
| 30 | Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. <i>Indian Journal of Gastroenterology</i> , 2022, 41, 169-180.   | 0.7 | 5         |
| 31 | Rifaximin enhances the L-carnitine-mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut-liver-muscle axis. <i>International Journal of Molecular Medicine</i> , 2022, 50, .  | 1.8 | 5         |
| 32 | Efficacy and tolerability of interferon-free regimen for patients with genotype 1 HCV infection. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 2743-2750.   | 0.8 | 4         |
| 33 | Clinical Significance of Gamma-Glutamyltranspeptidase Combined with Carbohydrate-Deficient Transferrin for the Assessment of Excessive Alcohol Consumption in Patients with Alcoholic Cirrhosis. <i>Medicines (Basel, Switzerland)</i> , 2021, 8, 39.  | 0.7 | 4         |
| 34 | The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria. <i>Journal of Clinical Medicine</i> , 2021, 10, 4838. | 1.0 | 4         |
| 35 | Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study. <i>Clinical Endoscopy</i> , 2022, 55, 434-442.   | 0.6 | 4         |
| 36 | Comparison of the efficacy and safety between palliative biliary stent placement and duct clearance among elderly patients with choledocholithiasis: a propensity score-matched analysis. <i>BMC Gastroenterology</i> , 2021, 21, 369.   | 0.8 | 2         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 1-1.         | 0.8 | 2         |
| 38 | Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 30.          | 0.8 | 0         |
| 39 | Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy. <i>In Vivo</i> , 2022, 36, 1477-1484. | 0.6 | 0         |